These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2008 related articles for article (PubMed ID: 31413525)

  • 1. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
    Personeni N; Pressiani T; Rimassa L
    Future Oncol; 2019 Jul; 15(21):2449-2462. PubMed ID: 31204849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
    Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
    J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib: a promising treatment for hepatocellular carcinoma.
    Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
    Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral chemotherapy for the treatment of hepatocellular carcinoma.
    Yamamoto S; Kondo S
    Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
    Zhang CH; Li M; Lin YP; Gao Q
    Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.